Spencer David M. 4
4 · BELLICUM PHARMACEUTICALS, INC · Filed Jan 4, 2019
Insider Transaction Report
Form 4
Spencer David M.
Chief Scientific Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2019-01-02−2,500→ 7,500 total→ Common Stock (2,500 underlying) - Exercise/Conversion
Common Stock
2019-01-03+1,562→ 93,059 total - Tax Payment
Common Stock
2019-01-03$3.20/sh−589$1,885→ 92,470 total - Exercise/Conversion
Common Stock
2019-01-02+2,500→ 92,439 total - Tax Payment
Common Stock
2019-01-02$3.33/sh−942$3,137→ 91,497 total - Exercise/Conversion
Restricted Stock Units
2019-01-03−1,562→ 3,125 total→ Common Stock (1,562 underlying)
Footnotes (5)
- [F1]Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of the Issuer common stock.
- [F2]Represents the number of shares withheld by and surrendered to the Issuer on January 2, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 2, 2018 for 10,000 shares.
- [F3]Represents the number of shares withheld by and surrendered to the Issuer on January 3, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 3, 2017 for 6,250 shares.
- [F4]The RSUs vest in four equal annual installments beginning on January 2, 2019.
- [F5]The RSUs vest in four equal annual installments beginning on January 3, 2018.